Present at the biotechnological revolution: Transformation of technological identity for a large incumbent pharmaceutical firm

Research Policy

Volumn 26, Issue 4-5, 1997, Pages 429-446

  Zucker, Lynne G ^a   Darby, Michael R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biotechnology; Collaboration; Incumbent; Pharmaceutical; Transformation

Indexed keywords

EID: 0000720954     PISSN: 00487333     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0048-7333(97)00017-6     Document Type: Article

References (37)

1. Aghion, P., Tirole, J., 1994. The management of innovation. Q. J. Econ. 109, 1185-1209.
2. Arora, A., Gambardella, A., 1994. Evaluating technological information and utilizing it: scientific knowledge, technological capability, and external linkages in biotechnology. J. Econ. Behav. Organization 24, 91-114.
3. Baum, J.A.C., 1996. Organizational ecology. In: Clegg, S.R., Hardy, C., Nord, W.R. (Eds.), Handbook of Organization Studies. Sage Publications, London, 77-114.
4. Cohen, S., Chang, A., Boyer, H., Helling, R., 1973. Construction of biologically functional bacterial plasmids in vitro. Proc. Natl. Acad. Sci. 70, 3240-3244.
5. Comanor, W.S., 1986. The political economy of the pharmaceutical industry. J. Econ. Literature 24, 1178-1217.
6. Cookson, C., 1995. Essential engineering: how different is biotechnology? Financial Times, April 25, p. 10.
7. Darby, M.R., L.G. Zucker, 1966. Star scientists, institutions, and the entry of Japanese biotechnology enterprises. Natl. Bureau of Economic Res. Working Paper No. 5795.
8. Demsetz, H., 1988. The theory of the firm revisited. J. Law, Econ. Organization 4, 141-161.
9. Dosi, G., 1982. Technological paradigms and technological trajectories: a suggested interpretation of the determinants and directions of technical change. Res. Policy 11, 147-162.
10. Eisenberg, R.S., 1987. Proprietary rights and the norms of science in biotechnology research. Yale Law J. 97, 177-231.
11. Friedman, M., 1976. Price Theory. Aldine Publishing, Chicago.
12. Hedberg, B., 1981. How organizations learn and unlearn. In: Nystrom, P.C., Starbuck, W.H. (Eds.), Handbook of Organizational Design, Vol. 1. Oxford Univ. Press, Oxford, pp. 3-27.
13. Henderson, R., 1993. Underinvestment and incompetence as responses to radical innovation: evidence from the photolithographic alignment industry. Rand J. Econ. 24, 248-270.
14. Henderson, R., Clark, K.B., 1990. Architectural innovation: the reconfiguration of existing product technologies and the failure of established firms. Administrative Sci. Q. 35, 9-30.
15. Kaufman, H., 1971. The Limits of Organizational Change. Univ. of Alabama Press, University, AL.
16. Kim, L., 1997. Imitation to Innovation: The Dynamics of Korea's Technological Learning. Harvard Business School Press, Boston.
17. Kimberly, J.R., Quinn, R.E., 1984. The challenge of transition management. In: Kimberly, J.R., Quinn, R.E. (Eds.), Managing Organizational Transitions. Richard D. Irwin, Homewood, IL.
18. Klevorick, A.K., Levin, R.C., Nelson, R.R., Winter, S.G., 1995. On the sources and significance of interindustry differences in technological opportunities. Res. Policy 24, 185-205.
19. Lee, K.B., Jr., Burrill, G.S., 1994. Biotech 95: Reform, Restructure, Renewal. The Ernst and Young Ninth Annual Report on the Biotechnology Industry. Ernst and Young, Palo Alto, CA.
20. Liebeskind, J.P., Oliver, A.L., Zucker, L.G., Brewer, M.B., 1996. Social networks, learning, and flexibility: sourcing scientific knowledge in new biotechnology firms. Organization Sci. 7, 428-443.
21. Lounamaa, P.H., March, J.G., 1987. Adaptive coordination of a learning team. Manage. Sci. 33, 107-123.
22. March, J.G., Simon, H.A., 1993. Organizations, 2nd edn., Blackwell, Cambridge, MA.
23. McCarthy, J.D., Wolfson, M., 1996. Resource mobilization by local social movement organizations: agency, strategy, and organization in the movement against drinking and driving. Am. Sociological Rev. 61, 1070-1088.
24. McCarthy, J.D., Zald, M.N., 1977. Resource mobilization and social movements: a partial theory. Am. J. Sociology 82, 1212-1241.
25. Nelson, R.R., Winter, S.G., 1982. An Evolutionary Theory of Economic Change. Harvard Univ. Press, Cambridge, MA.
26. Pisano, G.P., 1994. Knowledge, integration, and the locus of learning: an empirical analysis of process development. Strategic Manage. J. 15, 85-100.
27. Reinganum, J.F., 1983. Uncertain innovation and the persistence of monopoly. Am. Econ. Rev. 73, 741-748.
28. Reinganum, J.F., 1989. The timing of innovation: research, development, and diffusion. In: Schmalensee, R., Willig, R.D. (Eds.), Handbook of Industrial Organization, Vol. 1. North-Holland, New York, 849-908.
29. Sindelar, R.D., 1992. Overview/preview of current and future recombinant DNA-produced pharmaceuticals. Drug Topics, Suppl., April 20, 3-16.
30. Sindelar, R.D., 1993. The pharmacy of the future. Drug Topics 137 (9), 66-84.
31. Tolbert, P.S., L.G. Zucker, 1996, The institutionalization of institutional theory. In: Clegg, S.R., Hardy, C., Nord, W.R. (Eds.), Handbook of Organization Studies. Sage Publications, London, pp. 175-190.
32. Tushman, M.L., Anderson, P., 1986. Technological discontinuities and organizational environments. Administrative Sci. Q. 31, 439-465.
33. Waring, G.F., 1993. Industry differences in the persistence of competitive advantage, unpublished doctoral dissertation. Univ. of California, Los Angeles.
34. Zucker, L.G., Darby, M.R., 1996a. Costly information: firm transformation, exit, or persistent failure. Am. Behavioral Scientist 39, 959-974.
35. Zucker, L.G., Darby, M.R., 1996b. Star scientists and institutional transformation: patterns of invention and innovation in the formation of the biotechnology industry. Proc. Natl. Acad. Sci. 93, 12709-12716.
36. Zucker, L.G., Darby, M.R., Armstrong, J., 1997. Intellectual human capital and the firm: the technology of geographically localized knowledge spillovers. Economic Inquiry, in press.
37. Zucker, L.G., Darby, M.R., Brewer, M.B., 1997. Intellectual human capital and the birth of US biotechnology enterprises. Am. Econ. Rev., in press.